China
Africa
Explore chapters and articles related to this topic
Psoriasis
Published in Charles Theisler, Adjuvant Medical Care, 2023
Psoriasis is a chronic inflammatory skin disease that causes raised red patches of thick, itchy skin with silvery-white scales, most commonly on the knees, elbows, trunk, lower back, and scalp.1 Nails, eyebrows, and other areas may also be affected. There are several types of psoriasis. Generally, psoriasis causes cells to build up rapidly on the surface of the skin and results in the raised red patches and scales. The condition tends to run in families and usually appears in early adulthood.
Papulosquamous Diseases
Published in Ayşe Serap Karadağ, Lawrence Charles Parish, Jordan V. Wang, Roxburgh's Common Skin Diseases, 2022
Melek Aslan Kayıran, Jordan V. Wang, Ayşe Serap Karadağ
Course: Psoriasis is a chronic and recurring disease without cure. With appropriate use of topical and systemic agents and thorough patient education regarding treatment strategies, psoriasis can be managed. Severe forms, such as pustular psoriasis and erythrodermic psoriasis, may be life-threatening if not treated appropriately. In these patients, appropriate treatment should be initiated as soon as possible.
Bayesian Methods for Evaluating Drug Safety with Real-World Evidence
Published in Harry Yang, Binbing Yu, Real-World Evidence in Drug Development and Evaluation, 2021
Psoriasis is a chronic autoimmune disease in which the growth cycle of skin cells is accelerated. Genetic and environmental factors induce immune responses mediated by several cytokines and chemokines, including interleukin-17 (IL-17) [27, 28]. IL-17 is a cytokine that controls cells and activates inflammation. For healthy individuals without psoriasis, these molecules stimulate the body's immune system into action only when there is a cut or a scrape, sending cells to the surface to fight infection and heal a wound. Psoriasis patients have 30 times more IL-17 than healthy people. Research has shown that stopping IL-17, or reducing it, may help clear psoriasis.
Life quality among psoriasis patients based on Dermatology Life Quality Index evaluation and its association with psoriasis severity in China: a cross-sectional study
Published in Annals of Medicine, 2023
Yiran Chen, Lei Wei, Yu Song, Rui Zhang, Le Kuai, Bin Li, Ruiping Wang
To the best of our knowledge, this study is among the largest in China, involving 4230 patients with psoriasis, aiming to investigate the correlation between quality of life based on DLQI and psoriasis severity based on PASI. This considerable sample size provides a unique opportunity to gain deeper insights into the relationship between these two important aspects of psoriasis management. Psoriasis has a significant impact on quality of life by influencing daily activities, social functioning and psychological well-being throughout the patient’s lifetime. This study showed that the DLQI score was positively correlated with the PASI score, which indicated that patients with heavier psoriasis severity tended to have worse quality of life, which was similar to previous studies [5,17]. In this study, over 84% of the patients reported that psoriasis affected their quality of life from mild to severe. The reduction in quality of life among psoriasis patients might be due to the recurrence of psoriasis, the resistance response to treatment, long-term treatment-induced heavy financial burdens, anxiety, depression, low self-esteem, and the social stigmatization of psoriasis, which even tends to generate suicidal thoughts among patients, which also significantly impairs their quality of life [15,20,21]. The findings of this study demonstrated that psoriasis severity had a negative impact on the quality of life among psoriasis patients, which should be paid more attention in the process of patient treatment and management.
Histone deacetylase inhibitors as a potential new treatment for psoriatic disease and other inflammatory conditions
Published in Critical Reviews in Clinical Laboratory Sciences, 2023
Jehan Mohammad Nazri, Katerina Oikonomopoulou, Elvin D. de Araujo, Dziyana Kraskouskaya, Patrick T. Gunning, Vinod Chandran
There are five types of psoriasis: plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, and erythrodermic psoriasis. Plaque psoriasis, also known as psoriasis vulgaris, is the most common form (90%) of psoriasis. Some manifestations of plaque psoriasis include well-defined erythematous skin plaques with silvery scales that are often itchy and painful, appearing commonly on the trunk of the body, scalp, and extensor surfaces [4,5]. In contrast, guttate psoriasis involves smaller, dot-like erythematous plaques [6,7], while inverse psoriasis is a skin erosion of erythematous plaques [8]. Pustular psoriasis is characterized by pustules or small blisters rather than plaques [9], and in erythrodermic psoriasis (the most severe form of psoriasis), over 90% of the body is erythematous and inflamed [8].
Systematic literature review of long-term efficacy data for topical psoriasis treatments
Published in Journal of Dermatological Treatment, 2022
Claire Bark, Chloe Brown, Per Svangren
For completeness, 12-week studies were included in this review although they are not considered long-term from a regulatory perspective. Regulators indicate that studies of 8-12 weeks are usually required to demonstrate short-term efficacy (4 weeks for potent topical corticosteroids), and that one-year prolonged or intermittent use studies are recommended to demonstrate long-term safety and efficacy (84). In addition, previous SLRs of topical treatments for psoriasis included studies of at least 24 weeks as long-term (18,19) and have commented that long-term studies of topical treatments for psoriasis are lacking and studies such as PSO-LONG are needed to inform long-term management strategies (8,19). Such strategies have the potential to improve disease control and reduce the negative impact of psoriasis on patient’s lives, without the need for continuous daily treatment.